|
JPH0515775Y2
(enrdf_load_stackoverflow)
|
1987-07-13 |
1993-04-26 |
|
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
CA2339961C
(en)
|
1998-08-11 |
2009-01-20 |
Novartis Ag |
Isoquinoline derivatives with angiogenesis inhibiting activity
|
|
US6133031A
(en)
|
1999-08-19 |
2000-10-17 |
Isis Pharmaceuticals Inc. |
Antisense inhibition of focal adhesion kinase expression
|
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
WO2002000196A2
(en)
|
2000-06-28 |
2002-01-03 |
Smithkline Beecham P.L.C. |
Wet milling process
|
|
AU2002337142B2
(en)
|
2001-09-19 |
2007-10-11 |
Aventis Pharma S.A. |
Indolizines as kinase protein inhibitors
|
|
PT1441737E
(pt)
|
2001-10-30 |
2006-12-29 |
Dana Farber Cancer Inst Inc |
Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
|
|
PE20040522A1
(es)
|
2002-05-29 |
2004-09-28 |
Novartis Ag |
Derivados de diarilurea dependientes de la cinasa de proteina
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
TWI335913B
(en)
|
2002-11-15 |
2011-01-11 |
Vertex Pharma |
Diaminotriazoles useful as inhibitors of protein kinases
|
|
UA80767C2
(en)
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
US20060106020A1
(en)
|
2004-04-28 |
2006-05-18 |
Rodgers James D |
Tetracyclic inhibitors of Janus kinases
|
|
CN101106983A
(zh)
|
2004-11-24 |
2008-01-16 |
诺瓦提斯公司 |
JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
|
|
AR054416A1
(es)
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
|
EP1926735A1
(en)
|
2005-09-22 |
2008-06-04 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
SI2343299T1
(sl)
|
2005-12-13 |
2016-06-30 |
Incyte Holdings Corporation |
S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b) pirimidini kot zaviralci janus kinaze
|
|
CA2673038C
(en)
|
2006-12-22 |
2015-12-15 |
Incyte Corporation |
Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
|
|
CL2008001709A1
(es)
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
|
PT3070090T
(pt)
|
2007-06-13 |
2019-03-20 |
Incyte Holdings Corp |
Utilização de sais do inibidor da janus cinase (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo
|
|
US8309718B2
(en)
|
2007-11-16 |
2012-11-13 |
Incyte Corporation |
4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
|
CA2718271C
(en)
|
2008-03-11 |
2014-05-06 |
Incyte Corporation |
Azetidine and cyclobutane derivatives as jak inhibitors
|
|
CL2009001884A1
(es)
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
JOP20190231A1
(ar)
|
2009-01-15 |
2017-06-16 |
Incyte Corp |
طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
|
|
CN106967070A
(zh)
|
2009-05-22 |
2017-07-21 |
因塞特控股公司 |
作为jak抑制剂的化合物
|
|
AU2010249380B2
(en)
|
2009-05-22 |
2015-08-20 |
Incyte Holdings Corporation |
N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
PT2486041E
(pt)
|
2009-10-09 |
2013-11-14 |
Incyte Corp |
Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
|
|
EA023444B1
(ru)
|
2010-02-18 |
2016-06-30 |
Инсайт Холдингс Корпорейшн |
Циклобутановые и метилциклобутановые производные, композиции на их основе и способы их применения
|
|
ES2662588T3
(es)
|
2010-03-10 |
2018-04-09 |
Incyte Holdings Corporation |
Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
|
|
AU2011240808B2
(en)
|
2010-04-14 |
2015-01-22 |
Array Biopharma Inc. |
5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
|
|
SG10201910912TA
(en)
|
2010-05-21 |
2020-01-30 |
Incyte Corp |
Topical Formulation for a JAK Inhibitor
|
|
JOP20190250A1
(ar)
|
2010-07-14 |
2017-06-16 |
Regeneron Pharma |
صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
|
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
|
WO2012068450A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
CA2820109C
(en)
|
2010-12-10 |
2018-01-09 |
Rottapharm S.P.A. |
Pyridine amide derivatives as ep4 receptor antagonists
|
|
KR102024948B1
(ko)
|
2011-02-18 |
2019-11-04 |
노파르티스 파르마 아게 |
mTOR/JAK 저해제 병용 요법
|
|
US9926601B2
(en)
|
2011-02-24 |
2018-03-27 |
Massachusetts Institute Of Technology |
Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
HK1198579A1
(en)
|
2011-08-10 |
2015-04-30 |
Novartis Pharma Ag |
Jak p13k/mtor combination therapy
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
CA2849357A1
(en)
|
2011-09-22 |
2013-03-28 |
Merck Sharp & Dohme Corp. |
Acyclic cyanoethylpyrazoles as janus kinase inhibitors
|
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
|
PE20151141A1
(es)
|
2012-11-01 |
2015-08-06 |
Incyte Corp |
Derivados triciclicos fusionados de tiofeno como inhibidores de jak
|
|
HUE055894T2
(hu)
|
2012-11-15 |
2021-12-28 |
Incyte Holdings Corp |
A ruxolitinib nyújtott felszabadulású dózisformái
|
|
SI3489239T1
(sl)
|
2013-03-06 |
2022-04-29 |
Incyte Holdings Corporation |
Postopki in intermediati za pripravo zaviralca JAK
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
JP6533217B2
(ja)
|
2013-05-17 |
2019-06-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類
|
|
SI2997023T1
(sl)
|
2013-05-17 |
2017-07-31 |
Incyte Corporation |
Bipirazolni derivati kot inhibitorji JAK
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
US9371282B2
(en)
|
2013-05-17 |
2016-06-21 |
Centrexion Therapeutics Corporation |
Somatostatin receptor subtype 4 (SSTR4) agonists
|
|
CA2920108C
(en)
|
2013-08-07 |
2022-07-05 |
Incyte Corporation |
Sustained release dosage forms for a jak1 inhibitor
|
|
AU2014309017A1
(en)
|
2013-08-20 |
2016-03-10 |
Incyte Corporation |
Survival benefit in patients with solid tumors with elevated C-reactive protein levels
|
|
AU2014339897A1
(en)
*
|
2013-10-24 |
2016-04-21 |
Abbvie Inc. |
JAK1 selective inhibitor and uses thereof
|
|
US20150246046A1
(en)
|
2014-02-28 |
2015-09-03 |
Incyte Corporation |
Jak1 inhibitors for the treatment of myelodysplastic syndromes
|
|
US9802957B2
(en)
|
2014-04-30 |
2017-10-31 |
Incyte Corporation |
Processes of preparing a JAK1 inhibitor and new forms thereto
|
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
|
JP6697466B2
(ja)
|
2014-12-16 |
2020-05-20 |
ノバルティス アーゲー |
ＬｐｘＣ阻害剤としてのイソオキサゾールヒドロキサム酸化合物
|
|
TW201705961A
(zh)
*
|
2015-06-11 |
2017-02-16 |
阿爾米雷爾有限公司 |
作為ｊａｋ抑制劑的２－（吡唑并吡啶－３－基）嘧啶衍生物
|
|
ES2901795T3
(es)
|
2015-12-04 |
2022-03-23 |
Juno Therapeutics Inc |
Métodos y composiciones relacionadas con la toxicidad asociada con la terapia celular
|
|
EP3433276B1
(en)
|
2016-03-22 |
2021-12-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
|
JP7219376B2
(ja)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
|
|
KR20200036004A
(ko)
*
|
2017-08-01 |
2020-04-06 |
세라밴스 바이오파마 알앤디 아이피, 엘엘씨 |
Jak 키나아제 억제제로서 피라졸로 및 트리아졸로 비시클릭 화합물
|
|
TW201924683A
(zh)
|
2017-12-08 |
2019-07-01 |
美商英塞特公司 |
用於治療骨髓增生性贅瘤的低劑量組合療法
|
|
MD3746429T2
(ro)
|
2018-01-30 |
2022-08-31 |
Incyte Corp |
Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
|
|
PE20212186A1
(es)
*
|
2018-02-16 |
2021-11-11 |
Incyte Corp |
Inhibidores de la via de jak1 para el tratamiento de trastornos relacionados con citoquinas
|
|
IL318069A
(en)
|
2018-03-30 |
2025-02-01 |
Incyte Corp |
Using JAK inhibitors to treat hidradenitis suppurativa
|
|
US11584961B2
(en)
|
2018-03-30 |
2023-02-21 |
Incyte Corporation |
Biomarkers for inflammatory skin disease
|
|
CA3097025A1
(en)
|
2018-04-13 |
2019-10-17 |
Incyte Corporation |
Biomarkers for graft-versus-host disease
|
|
US11633399B2
(en)
|
2018-12-25 |
2023-04-25 |
Sol-Gel Technologies Ltd. |
Treatment of skin disorders with compositions comprising an EGFR inhibitor
|
|
HUE067909T2
(hu)
*
|
2019-04-24 |
2024-11-28 |
Theravance Biopharma R&D Ip Llc |
Pirimidin JAK-inhibitorok bõrbetegségek kezelésére
|
|
JP7518900B2
(ja)
*
|
2019-10-16 |
2024-07-18 |
インサイト・コーポレイション |
皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
|
|
US20210346279A1
(en)
|
2020-05-07 |
2021-11-11 |
Sol-Gel Technologies Ltd. |
Compositions comprising tapinarof for the treatment of pruritis
|
|
FI4157831T3
(fi)
|
2020-06-02 |
2024-12-02 |
Incyte Corp |
Menetelmiä jak1-estäjän valmistamiseksi
|